Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-20 of 37

Sort by

Sort Order Select

Journal Articles

Large B-cell lymphoma following CD19-directed CART-cell therapy failure: Impact of CAR construct on disease features and outcomes of subsequent therapies

Blood (2025) 146 (Supplement 1): 5501.

https://doi.org/10.1182/blood-2025-5501

Published: 2025

Journal Articles

Duration of lymphopenia after CAR-T cell therapy is associated with increased risk of non-melanoma skin cancers and decreased survival

Emeline Chong, Megan Jones, Guido Ghilardi, Luca Paruzzo, Sunita Dwivedy Nasta, Stefan Barta, Jakub Svoboda, Elise Chong, Jordan Carter, Colin Thomas, Michael Cook, Emily Tomasulo, Marco Ruella, Daniel Landsburg, Stephen Schuster

Blood (2025) 146 (Supplement 1): 3728.

https://doi.org/10.1182/blood-2025-3728

Published: 2025

Journal Articles

Bispecific antibody vs non-bispecific antibody systemic therapy as immediate next line treatment after chimeric antigen receptor T-cell (CART) failure in large B-cell lymphoma

Blood (2025) 146 (Supplement 1): 4502.

https://doi.org/10.1182/blood-2025-4502

Published: 2025

Journal Articles

IL18-armored CAR T cells in patients with CLL/SLL and Richter's transformation after prior BTK inhibitor and venetoclax failure

Blood (2025) 146 (Supplement 1): 2394.

https://doi.org/10.1182/blood-2025-2394

Published: 2025

Journal Articles

Evaluation of outcomes by line of therapy in marginal zone lymphoma: Real-world evidence from 10 US academic centers

Narendranath Epperla, John Sharp, Natalie Grover, Marcus Watkins, Reem Karmali, Pallawi Torka, Timothy Voorhees, Colin Thomas, Stefan Barta, Praveen Ramakrishnan Geethakumari, Nancy Bartlett, Geoffrey Shouse, Adam Olszewski

Blood (2025) 146 (Supplement 1): 4533.

https://doi.org/10.1182/blood-2025-4533

Published: 2025

Journal Articles

Real-world outcomes with bispecific antibody therapies for aggressive B-cell lymphomas in octogenarians

Blood (2025) 146 (Supplement 1): 3746.

https://doi.org/10.1182/blood-2025-3746

Published: 2025

Journal Articles

Early administration of CD20 x CD3 bispecific antibodies 4-6 weeks after CAR-T infusion for patients with residual or progressive large B cell lymphomas

Blood (2025) 146 (Supplement 1): 1952.

https://doi.org/10.1182/blood-2025-1952

Published: 2025

Journal Articles

Outcomes of patients with dual primary T-cell and B-cell lymphoid malignancies

Zachary Hing, Colin Thomas, Stephen Schuster, Daniel Landsburg, Sunita Dwivedy Nasta, Jakub Svoboda, Jordan Carter, Emeline Chong, Nicole Altomare, Reem Karmali, Venkata Preetam Sandeep Kaduluri, Cole Sterling, Danielle Miller, Zachary Frosch, Stefan Barta

Blood (2025) 146 (Supplement 1): 5409.

https://doi.org/10.1182/blood-2025-5409

Published: 2025

Journal Articles

Risk factors for CRS and NT with bispecific antibodies: Data from the American bispecifics and CART (ABC) consortium

Blood (2025) 146 (Supplement 1): 960.

https://doi.org/10.1182/blood-2025-960

Published: 2025

Journal Articles

Clinical features and outcomes of patients with non-erythrodermic mycosis fungoides with high blood tumor burden

Blood (2025) 146 (Supplement 1): 560.

https://doi.org/10.1182/blood-2025-560

Published: 2025

Journal Articles

Naive CD4+ at apheresis and disease control at infusion are associated with improved efficacy in second-line CAR T-cells

Blood (2025) 146 (Supplement 1): 2755.

https://doi.org/10.1182/blood-2025-2755

Published: 2025

Journal Articles

Impact of sequencing of CART vs bi-specific antibody on survival in relapsed/refractory large B-cell lymphoma: An analysis from the ABC consortium

Blood (2025) 146 (Supplement 1): 398.

https://doi.org/10.1182/blood-2025-398

Published: 2025

Journal Articles

Frontline experience with second generation covalent Bruton tyrosine kinase inhibitors for mantle cell lymphoma: A single center experience

Luke Maillie, Stefan Barta, Jordan Carter, Michael Cook, Mitchell Hughes, Daniel Landsburg, Sunita Dwivedy Nasta, Marco Ruella, Stephen Schuster, Jakub Svoboda, Colin Thomas, Emily Tomasulo, Elise Chong

Blood (2025) 146 (Supplement 1): 7119.

https://doi.org/10.1182/blood-2025-7119

Published: 2025

Journal Articles

Risk factors for failure to complete step-up-dosing of bispecific antibody therapy for B-cell lymphomas

Michael Cook, Emeline Chong, Ava Clifford, Daniel Landsburg, Sunita Dwivedy Nasta, Elise Chong, Stefan Barta, Jakub Svoboda, Jordan Carter, Colin Thomas, Emily Tomasulo, Stephen Schuster

Blood (2025) 146 (Supplement 1): 5522.

https://doi.org/10.1182/blood-2025-5522

Published: 2025

Journal Articles

Infections in patients with aggressive B-cell lymphomas treated with CD3xCD20 bispecific antibodies

Blood (2025) 146 (Supplement 1): 2709.

https://doi.org/10.1182/blood-2025-2709

Published: 2025

Journal Articles

Title first‑in‑human Phase 1 dose‑finding study (VIPER 101) of dual‑population autologous CD5‑deleted anti-CD5 CAR‑T (Senza5 CART5) cells in Relapsed/Refractory T‑cell lymphomas

Stefan Barta, Stephen Schuster, Jakub Svoboda, Jordan Carter, Elise Chong, Daniel Landsburg, Sunita Dwivedy Nasta, Ruchi Patel, Joseph Fraietta, Colin Thomas, Omar Elghawy, Ran Reshef, Aditya Nimmagadda, Lavanya Peddada, Adam Snook, Nicholas Siciliano, Rosemary Mazanet, Marco Ruella

Blood (2025) 146 (Supplement 1): 4174.

https://doi.org/10.1182/blood-2025-4174

Published: 2025

Journal Articles

A multicenter real-world analysis of combined chemotherapy followed by consolidative radiation versus chemotherapy alone in the management of early-stage Hodgkin lymphoma – the HODGKIN25 study

Blood (2025) 146 (Supplement 1): 3617.

https://doi.org/10.1182/blood-2025-3617

Published: 2025

Journal Articles

Cardiovascular outcomes of patients transitioned from ibrutinib to an alternate bruton tyrosine kinase inhibitor for hypertension and/or cardiovascular adverse events

Emily Tomasulo, Emeline Chong, Evani Patel, James Rudolph, Yejin Andrea Kim, Marco Ruella, Alex Watts, Wei-Ting Hwang, Mitchell Hughes, Jakub Svoboda, Daniel Landsburg, Elise Chong, Sunita Dwivedy Nasta, Stefan Barta, Colin Thomas, Michael Cook, Jordan Carter, Michael Fradley, Stephen Schuster

Blood (2025) 146 (Supplement 1): 5680.

https://doi.org/10.1182/blood-2025-5680

Published: 2025

Journal Articles

A retrospective multi-center review of the safety and efficacy of bispecific T-cell engagers in the management of post-transplant lymphoproliferative disorder – the bite PTLD study

Nikita Dave, Imran Nizamuddin, Neha Mehta-Shah, Edd Ricker, Jennifer Amengual, Robert Baiocchi, Timothy Voorhees, Stefan Barta, Jordan Carter, Elise Chong, Michael Cook, Daniel Landsburg, Stephen Schuster, Colin Thomas, Emily Tomasulo, Jakub Svoboda, Sunita Dwivedy Nasta

Blood (2025) 146 (Supplement 1): 1963.

https://doi.org/10.1182/blood-2025-1963

Published: 2025

Journal Articles

Real world comparison of commercial CAR T-cell constructs for the treatment of LBCL

Blood (2025) 146 (Supplement 1): 781.

https://doi.org/10.1182/blood-2025-781

Published: 2025

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Large B-cell lymphoma following CD19-directed CART-cell therapy failure: Impact of CAR construct on disease features and outcomes of subsequent therapies

Duration of lymphopenia after CAR-T cell therapy is associated with increased risk of non-melanoma skin cancers and decreased survival

Bispecific antibody vs non-bispecific antibody systemic therapy as immediate next line treatment after chimeric antigen receptor T-cell (CART) failure in large B-cell lymphoma

IL18-armored CAR T cells in patients with CLL/SLL and Richter's transformation after prior BTK inhibitor and venetoclax failure

Evaluation of outcomes by line of therapy in marginal zone lymphoma: Real-world evidence from 10 US academic centers

Real-world outcomes with bispecific antibody therapies for aggressive B-cell lymphomas in octogenarians

Early administration of CD20 x CD3 bispecific antibodies 4-6 weeks after CAR-T infusion for patients with residual or progressive large B cell lymphomas

Outcomes of patients with dual primary T-cell and B-cell lymphoid malignancies

Risk factors for CRS and NT with bispecific antibodies: Data from the American bispecifics and CART (ABC) consortium

Clinical features and outcomes of patients with non-erythrodermic mycosis fungoides with high blood tumor burden

Naive CD4+ at apheresis and disease control at infusion are associated with improved efficacy in second-line CAR T-cells

Impact of sequencing of CART vs bi-specific antibody on survival in relapsed/refractory large B-cell lymphoma: An analysis from the ABC consortium

Frontline experience with second generation covalent Bruton tyrosine kinase inhibitors for mantle cell lymphoma: A single center experience

Risk factors for failure to complete step-up-dosing of bispecific antibody therapy for B-cell lymphomas

Infections in patients with aggressive B-cell lymphomas treated with CD3xCD20 bispecific antibodies

Title first‑in‑human Phase 1 dose‑finding study (VIPER 101) of dual‑population autologous CD5‑deleted anti-CD5 CAR‑T (Senza5 CART5) cells in Relapsed/Refractory T‑cell lymphomas

A multicenter real-world analysis of combined chemotherapy followed by consolidative radiation versus chemotherapy alone in the management of early-stage Hodgkin lymphoma – the HODGKIN25 study

Cardiovascular outcomes of patients transitioned from ibrutinib to an alternate bruton tyrosine kinase inhibitor for hypertension and/or cardiovascular adverse events

A retrospective multi-center review of the safety and efficacy of bispecific T-cell engagers in the management of post-transplant lymphoproliferative disorder – the bite PTLD study

Real world comparison of commercial CAR T-cell constructs for the treatment of LBCL

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only